# OTC

## Overview
The OTC gene encodes the enzyme ornithine transcarbamylase, a mitochondrial enzyme that plays a pivotal role in the urea cycle, a critical metabolic pathway for detoxifying ammonia in the liver. As a member of the transferase family, ornithine transcarbamylase catalyzes the conversion of ornithine and carbamoyl phosphate into citrulline, facilitating the subsequent production of urea. This process is essential for maintaining nitrogen balance and preventing hyperammonemia. The enzyme is predominantly expressed in the liver and intestine, and its activity is modulated by post-translational modifications such as acetylation. Mutations in the OTC gene can lead to ornithine transcarbamylase deficiency, an X-linked genetic disorder characterized by impaired ureagenesis and hyperammonemia, with a wide range of clinical manifestations (Couchet2021Ornithine; Yamaguchi2006Mutations).

## Structure
The human ornithine transcarbamylase (OTC) enzyme is a crucial component of the urea cycle, primarily located in the mitochondria. The mature human OTC protein consists of 321 amino acids and forms homotrimers in eukaryotes, exhibiting exact 3-fold symmetry (Couchet2021Ornithine; Shi2000Crystal). Each monomer of the OTC enzyme is structured into two distinct domains: the carbamoyl phosphate binding domain (CPBD) and the ornithine binding domain (OBD), connected by interdomain helices (Sundaresan2015Crystal; Shi2000Crystal). These domains feature a central parallel β-sheet surrounded by α-helices, forming an αβα-topology (SHI2001Human; Couchet2021Ornithine).

The active site of OTC is located in the cleft between the two domains and is shared by adjacent monomers, involving conserved motifs such as Ser-Thr-Arg-Thr-Arg for carbamoyl phosphate binding (SHI2001Human; Couchet2021Ornithine). Post-translational modifications, such as acetylation at lysine 88, can modulate the enzyme's activity by affecting substrate binding (Couchet2021Ornithine). The enzyme's structure is essential for its function in the urea cycle, facilitating substrate recognition and catalysis (SHI2001Human).

## Function
Ornithine transcarbamylase (OTC) is a mitochondrial enzyme that plays a critical role in the urea cycle, a metabolic pathway essential for detoxifying ammonia in the liver. In healthy human cells, OTC catalyzes the conversion of ornithine and carbamoyl phosphate into citrulline, a reaction that is vital for the subsequent production of urea from ammonia, thereby preventing hyperammonemia (Couchet2021Ornithine). The enzyme is primarily active in the liver and intestine, with its expression regulated by liver-specific transcription factors and influenced by nutritional states, such as high-protein diets (Couchet2021Ornithine).

OTC is synthesized in the cytoplasm and imported into the mitochondria, where it assembles into homotrimers. Its activity is modulated by secondary modifications, such as acetylation, which can decrease its function, while deacetylation by Sirt3 enhances it (Couchet2021Ornithine). The enzyme's function is closely linked to its structural conformation, which changes upon substrate binding, facilitating efficient substrate exchange and product formation within the urea cycle (Couchet2021Ornithine). This spatial organization and interaction with other urea cycle enzymes are crucial for maintaining nitrogen balance in healthy human cells (Couchet2021Ornithine).

## Clinical Significance
Mutations in the OTC gene lead to ornithine transcarbamylase deficiency (OTCD), the most common urea cycle disorder. This X-linked genetic condition results in impaired ureagenesis, causing hyperammonemia, which can lead to severe neurological damage and even death if untreated (Peng2020Clinical; Yamaguchi2006Mutations). The disorder is highly pleomorphic, with symptoms ranging from acute neonatal hyperammonemia in hemizygous males to later-onset manifestations in heterozygous females and males with partial defects (Peng2020Clinical; Kido2022Pathogenic).

The clinical presentation of OTCD varies widely, influenced by both genetic mutations and environmental factors such as infections and dietary protein intake (Peng2020Clinical). Mutations in the OTC gene are predominantly single-base substitutions, but deletions, insertions, and splice site errors also occur (Kido2022Pathogenic; Caldovic2015Genotype–Phenotype). Some common polymorphisms, like p.Lys46Arg and p.Gln270Arg, can act as genetic modifiers, potentially altering the severity of the disorder by affecting enzymatic activity (Lopes‐Marques2021Common).

Treatment options include dietary management, pharmacological interventions, and liver transplantation, though these do not always prevent neurological damage or mortality (Peng2020Clinical). Understanding the genotype-phenotype correlations is crucial for predicting disease severity and guiding treatment strategies (Caldovic2015Genotype–Phenotype).

## Interactions
Ornithine transcarbamylase (OTC) participates in several interactions crucial for its function in the urea cycle. It forms dish-like homotrimers, with active sites located at the concave face of the trimer, facilitating its catalytic activity (Couchet2021Ornithine). OTC interacts with mitochondrial carbamoyl phosphate synthetase 1 (CPS1), which catalyzes the first step of the urea cycle. This interaction suggests a mechanism of metabolite channeling, where CPS1 and OTC co-localize at the mitochondrial inner membrane, potentially forming complexes that regulate the flow of carbamoyl phosphate into the OTC reaction (Couchet2021Ornithine).

The enzyme also interacts with N-acetylglutamate synthase (NAGS), which regulates CPS1 activity, indicating a coordinated regulation of the urea cycle enzymes (Caldovic2022Assessing). These interactions are essential for efficient nitrogen metabolism and the prevention of metabolic disorders. The structural organization and interactions among these enzymes facilitate efficient metabolite flux and channeling within the cycle, ensuring the proper functioning of the urea cycle (Couchet2021Ornithine). These interactions highlight the importance of OTC in maintaining metabolic balance and its role in the broader network of mitochondrial enzymes.


## References


[1. (Sundaresan2015Crystal) Ramya Sundaresan, Akio Ebihara, Seiki Kuramitsu, Shigeyuki Yokoyama, Thirumananseri Kumarevel, and Karthe Ponnuraj. Crystal structure analysis of ornithine transcarbamylase from thermus thermophilus – hb8 provides insights on the plasticity of the active site. Biochemical and Biophysical Research Communications, 465(2):174–179, September 2015. URL: http://dx.doi.org/10.1016/j.bbrc.2015.07.096, doi:10.1016/j.bbrc.2015.07.096. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2015.07.096)

[2. (Couchet2021Ornithine) Morgane Couchet, Charlotte Breuillard, Christelle Corne, John Rendu, Béatrice Morio, Uwe Schlattner, and Christophe Moinard. Ornithine transcarbamylase – from structure to metabolism: an update. Frontiers in Physiology, October 2021. URL: http://dx.doi.org/10.3389/fphys.2021.748249, doi:10.3389/fphys.2021.748249. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2021.748249)

[3. (Yamaguchi2006Mutations) Saori Yamaguchi, Lisa L. Brailey, Hiroki Morizono, Allen E. Bale, and Mendel Tuchman. Mutations and polymorphisms in the human ornithine transcarbamylase (otc) gene. Human Mutation, 27(7):626–632, July 2006. URL: http://dx.doi.org/10.1002/humu.20339, doi:10.1002/humu.20339. This article has 128 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20339)

[4. (SHI2001Human) Dashuang SHI, Hiroki MORIZONO, Xiaolin YU, Liang TONG, Norma M. ALLEWELL, and Mendel TUCHMAN. Human ornithine transcarbamylase: crystallographic insights into substrate recognition and conformational changes. Biochemical Journal, 354(3):501–509, March 2001. URL: http://dx.doi.org/10.1042/bj3540501, doi:10.1042/bj3540501. This article has 32 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3540501)

[5. (Peng2020Clinical) Min-Zhi Peng, Xiu-Zhen Li, Hui-Fen Mei, Hui-Ying Sheng, Xi Yin, Min-Yan Jiang, Yan-Na Cai, Ling Su, Yun-Ting Lin, Yong-Xian Shao, and Li Liu. Clinical and biochemical characteristics of patients with ornithine transcarbamylase deficiency. Clinical Biochemistry, 84:63–72, October 2020. URL: http://dx.doi.org/10.1016/j.clinbiochem.2020.06.011, doi:10.1016/j.clinbiochem.2020.06.011. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.clinbiochem.2020.06.011)

[6. (Lopes‐Marques2021Common) Mónica Lopes‐Marques, Ana Rita Pacheco, Maria João Peixoto, Ana Rita Cardoso, Catarina Serrano, António Amorim, Maria João Prata, David N. Cooper, and Luísa Azevedo. Common polymorphic otc variants can act as genetic modifiers of enzymatic activity. Human Mutation, 42(8):978–989, June 2021. URL: http://dx.doi.org/10.1002/humu.24221, doi:10.1002/humu.24221. This article has 5 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.24221)

[7. (Kido2022Pathogenic) Jun Kido, Keishin Sugawara, Takaaki Sawada, Shirou Matsumoto, and Kimitoshi Nakamura. Pathogenic variants of ornithine transcarbamylase deficiency: nation-wide study in japan and literature review. Frontiers in Genetics, October 2022. URL: http://dx.doi.org/10.3389/fgene.2022.952467, doi:10.3389/fgene.2022.952467. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.952467)

[8. (Shi2000Crystal) Dashuang Shi, Hiroki Morizono, Mika Aoyagi, Mendel Tuchman, and Norma M. Allewell. Crystal structure of human ornithine transcarbamylase complexed with carbamoyl phosphate and l-norvaline at 1.9 ? resolution. Proteins: Structure, Function, and Genetics, 39(4):271–277, June 2000. URL: http://dx.doi.org/10.1002/(SICI)1097-0134(20000601)39:4<271::AID-PROT10>3.0.CO;2-E, doi:10.1002/(sici)1097-0134(20000601)39:4<271::aid-prot10>3.0.co;2-e. This article has 48 citations.](https://doi.org/10.1002/(SICI)1097-0134(20000601)39:4)

[9. (Caldovic2015Genotype–Phenotype) Ljubica Caldovic, Iman Abdikarim, Sahas Narain, Mendel Tuchman, and Hiroki Morizono. Genotype–phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. Journal of Genetics and Genomics, 42(5):181–194, May 2015. URL: http://dx.doi.org/10.1016/j.jgg.2015.04.003, doi:10.1016/j.jgg.2015.04.003. This article has 113 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jgg.2015.04.003)

[10. (Caldovic2022Assessing) Ljubica Caldovic, Shivaprasad Bhuvanendran, and Jyoti Jaiswal. Assessing Protein Interactions for Clustering of Mitochondrial Urea Cycle Enzymes, pages 73–92. Springer US, 2022. URL: http://dx.doi.org/10.1007/978-1-0716-2269-8_5, doi:10.1007/978-1-0716-2269-8_5. This article has 0 citations.](https://doi.org/10.1007/978-1-0716-2269-8_5)